Immix Biopharma is a clinical-stage biopharmaceutical company engaged in the development of a class of Tissue-Specific Therapeutics (TSTx) in oncology and inflammation. Co.'s primary asset, IMX-110, is for the treatment of solid tumors. IMX-110 is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer, utilizing Co.'s TME Normalization Technology, delivered deep into the tumor micro-environment (TME). Co.'s TME Normalization Technology allows its drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. The IMMX stock yearly return is shown above.
The yearly return on the IMMX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMMX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|